Genpact (G) looks 30–40% undervalued; Q4 beat and margin expansion from tech-driven contracts support a $43 target (15% ...

In Q3, Occidental Petroleum reported adjusted EPS of $0.64 on revenue of $6.72B, which fell 6% Y/Y. The firm has already ...

Novo Nordisk stock experienced a sharp decline after disappointing 2025 results and 2026 outlook but has seen a bounce back ...

For the full year, normalized FFO was $110.1 million or $1.08 per diluted share. FFO was $79.4 million or $0.78 per diluted ...

Q4 2025 earnings call highlights: 2026 sales/EPS guidance, utility demand & capex, ag margin recovery, Brazil risks, M&A—read ...

S&P 500 Index’s trailing 10-yr return has edged up since our performance outlook in November but today’s revised forecast for ...

Guidance shifted from a 2025 adjusted EPS range of $8.10 to $8.20 to a 2026 range of $8.70 to $8.90, reflecting higher ...

I believe silver is in a speculative bubble and recommend a strong sell after its recent meteoric surge. SLV's extreme ...

Bayer is preparing to announce a $10.5B settlement push to resolve current and future cancer lawsuits over its Roundup ...

Evercore says IBM’s 2026 free cash flow target of $15.7B is beatable, citing net income and software tailwinds plus Confluent ...

Labcorp (LH) stock dips as the company posts mixed Q4 2025 financials, falling short of Street forecasts for revenue while ...

The Wasatch U.S. Select Fund—Investor Class also finished in negative territory but outperformed the benchmark, with a ...